Eric Lau Archives - Sanford Burnham Prebys
Institute News

A former Sanford Burnham Prebys postdoc writes about science and social responsibility

AuthorScott LaFee
Date

October 18, 2023

The laboratory, with its precise protocols and sterile tools, seems far removed from the often discordant chaos of U.S. society. But science does not happen in a socio-political vacuum, says  Eric Lau, PhD, a former student and postdoc at Sanford Burnham Prebys, and research institutions shouldn’t pretend otherwise.

Writing in Nature Reviews Cancer, Lau, now an Assistant Professor in the Department of Tumor Microenvironment & Metastasis at the Moffitt Cancer Center & Research Institute in Tampa, Fl., calls for scientific institutions to become proactive against discrimination and to speak out against oppression while prioritizing diversity, equity and inclusion.

In a deeply personal essay, Lau chronicles his personal struggles to overcome both xenophobia and the “delusional and detrimental model minority myth” of Asian-American kids, plus persistent homophobia and hate-mongering.

Eric Lau headshot in lab coat with old Sanford-Burnham logoScience and the relationships formed with mentors, such as Kristiina Vuori, Wei Jiang, Robert Abraham, Gen-Sheng Feng and Ze’ev Ronai, as well as a handful of close colleagues at Sanford Burnham Prebys, were life- and career-affirming, he said, “but sadly all too rarely seen in the broader world.”

“Our nation claims to celebrate diversity and immigration….Yet racism and xenophobia are being amplified by governors who viciously traffic vulnerable migrants to other states and by Supreme Court justices who eviscerate affirmative action and approve anti-LGBT+ discrimination,” Lau writes.

“As much as most researchers might prefer to ‘just focus on the science,’ we cannot expect our teams to produce the best science if we turn a blind eye to those being discriminated or the discriminators.”

Willful ignorance and complacency are not options.

Lau says research institutions can and should take actions to mitigate the socio-political adversity that burdens their team members. Leadership cannot be performative—rather, it must be substantive, transparent and persistent. DEI programs must be built to produce intended results, with zero-tolerance for discrimination.

Lau concludes with a version of Martin Niemoller’s poem “First they came,” written in 1946 about the silence of German intellectuals and clergy (including Niemoller) during the rise of Nazism.
 

First they came for the socialists, and I did not speak out—
Because I was not a socialist.
Then they came for the trade unionists, and I did not speak out—
Because I was not a trade unionist.
Then they came for the Jews, and I did not speak out—
Because I was not a Jew.
Then they came for me—and there was no one left to speak for me.

 

Scientists, says Lau, must speak up and often.
For themselves.
For others.
For everyone.

Institute News

Meet a cancer researcher: Eric Lau

AuthorKristina Meek
Date

April 13, 2012

Meet Eric Lau, PhD, a postdoctoral researcher in Sanford-Burnham’s NCI-designated Cancer Center.

1.  What inspired you to pursue cancer research?

I spent a large portion of my childhood and early adulthood being raised alongside my grandmother. In 1997, my grandmother was diagnosed with advanced stage lung cancer. Over several months, I witnessed the immense suffering and downfall of this woman, who for most of my life, had represented a vibrant figure of strength and resilience. It was then that I knew that I wanted to devote my life to helping people through medical care or related research.

2.  What do you do?

I am a postdoctoral research fellow in the laboratory of Ze’ev Ronai, PhD I study the role of a protein called ATF2 in melanoma development and progression. ATF2 is a protein that can regulate a vast array of gene expression and therefore can contribute to many cellular behaviors and processes. ATF2 exhibits an intriguing duality in melanoma: it is able to both promote and to suppress melanoma and non-melanoma skin cancer progression. We found that a protein called PKCɛ can determine which role ATF2 plays and are currently investigating how both proteins coordinately contribute to melanoma and skin cancer development and progression. We are also screening for chemical compounds that may promote the anti-tumor functions of ATF2.

Malignant melanoma is the most lethal skin cancer and it develops striking resistance to even the most recent treatments—thus there is an urgent need for the identification and development of alternate therapeutic approaches. The findings from our screening efforts may uncover new therapeutic modalities for melanoma and other cancers that rely on PKCɛ and ATF2.

3.  What would you do with an extra $1 million?

One of my ongoing career goals is to establish my own independent, creative research team to continue investigating the molecular mechanisms that are critical for cancer development and progression. However, the dearth of current federal funding and the difficulty to secure and maintain such funding pose the biggest hurdles for the transition of young scientists to stable, independent investigator positions. If given $1 million, I would outfit my future laboratory with cutting-edge equipment and reagents, and hire laboratory personnel—postdocs, graduate students and technicians—required to continue our research. I would ensure that this funding would help me to maintain a supportive and creative environment for both scientific learning and discovery of the fellows employed in my laboratory.